By employing a patient-centered medical home (PCMH) model of care, Boston Medical Center's (BMC) Adult Primary Care Practice successfully treated 66 patients with the hepatitis C virus (HCV), or one-fifth of those referred ...
May 9, 2017
0
1
(HealthDay)—Hepatitis B virus (HBV) reactivation (HBV-R) is a safety concern for patients with HBV and hepatitis C virus (HCV) coinfection receiving direct-acting antiviral agents (DAAs), according to a study published ...
Apr 25, 2017
0
0
A study presented today that evaluated an investigational dosage of once-daily ledipasvir 45 mg/sofosbuvir 200 mg (LDV/SOF) in children aged six to 11 years infected with the Hepatitis C virus (HCV), found that 99% of children ...
Apr 21, 2017
0
1
Study results presented today demonstrate that the oral, once-daily treatment regimen of glecaprevir/pibrentasvir (G/P) resulted in 95% sustained virologic response rates at 12 weeks post treatment (SVR12) in patients with ...
Apr 21, 2017
0
0
FDA-approved oral direct-acting antiviral (DAA) regimens produce high sustained virologic response (SVR) rates for all six hepatitis C virus (HCV) genotypes and for patient populations historically considered difficult to ...
Mar 20, 2017
0
0
Researchers at the European Bioinformatics Institute (EMBL-EBI) have shown that the health of individual mice is influenced by the genetic makeup of their partners. Their findings, published in PLOS Genetics, indicate that ...
Jan 25, 2017
0
10
The drug combination sofosbuvir/velpatasvir (trade name: Epclusa) has been approved since July 2016 for the treatment of patients with chronic hepatitis C (CHC). In an early benefit assessment, the German Institute for Quality ...
Oct 17, 2016
0
1
(HealthDay)—Men with phimosis have increased prevalence of human papillomavirus (HPV) and high-risk HPV genotypes compared with asymptomatic men, according to a study published in the June issue of The Journal of Urology.
Jun 16, 2016
0
0
People who have reduced enzyme activity to breakdown active aldehyde, i.e., those who become easily inebriated, are more likely to develop fatty liver disease even if they do not drink alcohol. This discovery was made by ...
May 24, 2016
0
31
A Hepatitis C (HCV) drug currently under investigation, ABT-493 and ABT-530, which is an all-oral once-daily antiviral treatment, helped HCV genotype 3 patients with heavily scarred livers and no previous treatment history ...
Apr 16, 2016
0
4
